At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im (Dongguk University, Korea). The products fall into three tiers: symptom-modifying, biologic/regenerative and structure-oriented. The pipeline is encouraging, but the evidence is uneven and often thin.
All News
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and potential future targeted therapies. This review builds on other important reports on CPPD.
DMARD in OA? #ACR26 @RheumNow Ab#0871 TRIUMPH-4 Retatrutide in Knee OA - GIP/GLP1/gluc rec ago 9mg/12 mg v PBO WOMAC reduction w16, sustained thro w68 Wt dec 29% (32 kg) at wk68 78% on RETA had 50%+ WOMAC pain improvement Discontinuation from AE -13/18%, 46% due to GI AE #ACRBest https://t.co/a9qGtZx5t9
